Breaking News

Ferring Pharmaceuticals Opens New Manufacturing Site in Finland

Bolsters its manufacturing capabilities to meet anticipated growth in demand for Adstiladrin (nadofaragene firadenovec-vncg).

Author Image

By: Charlie Sternberg

Associate Editor

Ferring Pharmaceuticals has opened a new global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin (nadofaragene firadenovec-vncg). This represents a significant milestone in Ferring’s capabilities and capacity to meet the growth in demand for this gene therapy for people with non-muscle invasive bladder cancer (NMIBC).   Adstiladrin (nadofaragene firadenovec-vncg) is approved in the U.S. for adult patients with high-risk Bacillus C...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters